Skip navigation.
Home
Last Updated: Friday 10 October 2008 19:05 GMT | [Write for us] | [Subscribe to RSS] | [Advertise with us] [Editor's Blog]

Gene Status, Key In Reaping Erbitux’s Benefits: Study

Gene Status, Key In Reaping Erbitux’s Benefits: Study

Testing for the gene mutation would help determine in advance whether a colondefine cancerdefine patient will benefit from treatment with ImClone Systems' drug Erbitux, a new research from Eurpoe claims.

Colondefine cancers triggered from the normal form of gene, the KRAS, respond best to an important class of cancerdefine drugs, known as EGFR inhibitors (Imclone’s Erbitux and Amgen’s Vectibix), than tumors with a common mutation of the gene, the facts presented at the 44th Annual Meeting of the American Society of Clinical Oncology held in Chicago on Sunday, confirmed.

Researchers examined tissue samples of a little less than 600 patients undergoing initial treatment for advanced colorectal cancer. While, all patients were administered a drug combination called Folfiri, some also got Erbitux.

While, 59 percent of the patients with normal KRAS gene responded to Erbitux combination treatment and their tumors shrank by more than half, 43 percent of those who took chemotherapy alone posted no major benefits.

Moreover, amongst all patients with normal KRAS, those treated with Erbitux posted a 32 percent reduction in the risk of tumor progression and recurrence, compared with the 15 percent reduced risk, which was for all patients, during the risk study.

"KRAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis," urged study’s lead author Dr. Eric Van Cutsem, professor at the University Hospital Gasthuisberg in Leuven, Belgium. "If you focus on the KRAS patients, you see a much bigger benefit, which is clinically very important," he claimed.

The testing for gene mutation costs between $500 and $1,000, while Erbitux costs between $8,000 and $10,000 a month.

Erbitux is a monoclonal antibody naturally produced by the immune systemdefine in response to infection. As the normal standard KRAS gene transmits signals for cell division and is associated with uncontrolled division of tumor cells, the Erbitux treatment attacks the cancer cells by latching onto them and blocking their replication.

"These findings are very important for patients and also for clinicians, as we have shown that, using this KRAS test, we can predict which patients will benefit and which will not benefit from Erbitux," said Cutsem.

"We have shown that the activity of Erbitux is confined to the patients with the KRAS tumor so, if we know in advance that a patient has the mutation, we know that we don't have to treat them with Erbitux," he concluded.


Subscribe to RSS Feeds Subscribe for free via email, or grab our feed.
 

Weaning is the gradual replacement of breastfeeding with other foods and ways of nurturing. If done gradually, weaning can be a positive experience for both the mother and the little one.

ABC of Weaning

Weaning is the process of gradually introducing the infant to solid diet and reducing the supply of mother’s milk. A fully weaned infant derives all its nutrition from solid foods and is off breast milk completely.

    "It is not about money. No amount of money will give back my limb," said a 65 years old woman with diabetes (name withheld on request) who underwent limb amputation at the Gandhi Memorial & Associated Hospitals (GM & AH), India.

    People with diabetes lose more than money

    She couldn't have been right in conveying the message in the lead up to the World Diabetes Day, 14 November 2008, to prevent many diabetes-related complications that are extremely devastating.

      Aromatherapy – More Than Just Good Smell

      Aromatherapy is a form of alternative healing that makes use of volatile plant oils, referred to as essential oils, and other aromatic compounds obtained from plants for the overall physical and psychological well-being of a person.